Hara, Hiroki
Satoh, Taroh
Kojima, Takashi
Tsushima, Takahiro
Sunakawa, Yu
Okada, Morihito
Ding, Ningning
Wu, Hongqian
Li, Liyun
Yu, Tian
Barnes, Gisoo
Kato, Ken http://orcid.org/0000-0002-1733-5072
Clinical trials referenced in this document:
Documents that mention this clinical trial
79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
https://doi.org/10.1136/jitc-2020-sitc2020.0079
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
https://doi.org/10.1136/jitc-2019-000437
Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.
https://doi.org/10.1200/jco.2024.42.16_suppl.e14617
Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).
https://doi.org/10.1200/jco.2024.42.3_suppl.390
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
https://doi.org/10.1007/s10388-023-01040-w
Funding for this research was provided by:
BeiGene, Ltd
Article History
Received: 11 July 2023
Accepted: 14 December 2023
First Online: 19 January 2024
Declarations
:
: The study was carried out in accordance with the International Conference on Harmonisation Good Clinical Practice Guideline, the principles of the Declaration of Helsinki, and local laws and regulations. The protocol was approved by the relevant Institutional Review Board/Independent Ethics Committee for participating study sites. All patients provided written informed consent before participation.
: HH has received grants from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi-Sankyo, Dainippon Sumitomo, Janssen, Merck Biopharma, MSD, Ono Pharmaceutical and Taiho Pharmaceutical; has served in consulting roles for Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Dainippon Sumitomo, MSD and Ono Pharmaceutical; and has received honoraria from Bayer, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi-Sankyo, Kyowa Hakko Kirin, Lilly, Merck Biopharma, MSD, Ono Pharmaceutical, Sanofi, Taiho Pharmaceutical, Takeda, Yakult and Asahi Kasei. TSa has received grants from Chyai Pharmaceutical, Ono Pharmaceutical and Yakult Honsha; and has received honoraria from Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi-Sankyo, Eli-Lilly and Ono Pharmaceutical. TK has received grants from Amgen, BeiGene, Bristol-Myers Squibb, Chugai Pharmaceutical, EPS Corporation, MERCK Biopharma, MSD, Ono Pharmaceutical, Parexel International and Taiho Pharmaceutical; has received payments from Bristol-Myers Squibb, Covidien Japan Inc, MSD, Oncolys Biopharma, Ono Pharmaceutical and Taiho Pharmaceutical; and has participated on a data safety monitoring board or advisory board for Astellas Pharma, Bristol-Myers Squibb, Merck Biopharma, MSD and Oncolys Biopharma. TT has received honoraria from Taiho Pharmaceutical, MSD, Bristol-Myers Squibb and Ono Pharmaceutical. ND is an employee of BeiGene with stock or stock options. HW is an employee of BeiGene with stock or stock options. LL is an employee of BeiGene and has received a grant from BeiGene; has received support for attending meetings and/or travel from BeiGene; and has stock or stock options with BeiGene. TY is an employee of BeiGene with stock or stock options. GB is an employee of BeiGene; has received support for travel from BeiGene; and has stock or stock options with BeiGene. KK has received consulting fees from AstraZeneca, Bayer, BeiGene/Novartis, Bristol-Myers Squibb, Merck Biopharma, Ono Pharmaceutical and Roche; has received honoraria from Bristol-Myers Squibb and Ono Pharmaceutical; and has participated in a data safety monitoring board or advisory board for Bristol-Myers Squibb, Merck Biopharma and Ono Pharmaceutical. The remaining authors declare that they have no conflicts of interest.